| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5499 | Vzmc013 | Novel Probe of Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity |
|
| DCC5500 | w-13 Hydrochloride Featured | W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
|
| DCC5501 | w-5 Hydrochloride | Calmodulin antagonist, inhibiting Ca2+/calmodulin-regulated enzyme activities |
|
| DCC5502 | waladin1 | Mixed competitive/noncompetitive inhibitor of |
|
| DCC5503 | Wallichoside | Nocel inhibitor of BMI1 promoter activity, decreasing BMI1 protein levels in HCT116 human colon carcinoma cells, significantly reducing levels of the CSC biomarker epithelial cell adhesion molecule and diminishing the self-renewal capability of CSCs |
|
| DCC5504 | Way103 | Very late adhesion molecule 4 (VLA-4) antagonist, inhibiting VLA-4/VCAM-1 ligation as a means of modulating eosinophil functions beyond its action on cell adhesion and migration |
|
| DCC5505 | Way-123783 | SGLT2 inhibitor |
|
| DCC5506 | way-133537 | ATP-sensitive potassium channel opener |
|
| DCC5507 | Way-151693 | Inhibitor of human collagenase-3 (MMP-13) |
|
| DCC5508 | Way-170523 | Potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3) |
|
| DCC5509 | Way-171230 | Inhibitor of matrix metalloproteinase-1 (MMP-1) |
|
| DCC5510 | Way-260022 | Potent and Selective Inhibitor of the Norepinephrine Transporter |
|
| DCC5511 | Way-316606 Hydrochloride | Secreted frizzled-related protein-1 (sFRP-1) modulaitor |
|
| DCC5512 | Wb-308 | Novel inhibitor of The epidermal growth factor receptor (EGFR), decreasing NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis. |
|
| DCC5513 | Wb4-24 | Non-peptide GLP-1 receptor agonist, blocking inflammatory nociception by stimulating β-endorphin release from spinal microglia |
|
| DCC5514 | Wck5153 | Novel Inhibitor of PBP2, Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones |
|
| DCC5515 | We-14 Tfa Salt | Highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1) |
|
| DCC5516 | Web2347 | Novel very potent and long acting hetrazepinoic PAF-antagonist |
|
| DCC5517 | Wen05-03 | Novel inhibitor of type III secretion system ATPase EscN from enteropathogenic Eecherichia coli |
|
| DCC5518 | Wfq-228 | Novel fluoroquinolone antibiotic with potent antimicrobial activity, showing the potential to overcome major drug resistance; its antimicrobial activity was less affected by both pump-mediated efflux and QRDR mutations in P. aeruginosa compared with LVX a |
|
| DCC5519 | Whz-04 | Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor |
|
| DCC5520 | Win-35428 | Dopamine reuptake inhibitor, also having some SERT affinity |
|
| DCC5521 | Win-64338 | B2 bradykinin receptor antagonist |
|
| DCC5522 | Withangulatin A | Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2 |
|
| DCC5523 | Wj35435 | Novel dual inhibitor of histone deacetylase and topoisomerase I |
|
| DCC5524 | Wjd008 | Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant |
|
| DCC5525 | Wms-1410 | Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen |
|
| DCC5526 | Wms-2539 | Potent uncompetitive NMDA receptor antagonist |
|
| DCC5527 | Wn1316 | Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS) |
|
| DCC5528 | Wnk-in-3 | Novel Allosteric WNK Kinase Inhibitor |
|
